Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CODX

Co-Diagnostics Inc

Apr 15 • 11:46AM ET

1.38

0.00 0.00 %

Healthcare • Medical Devices • USA • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-31.01	Insider Own	8.57%	Shs Outstand	3.60M	Perf Week	-0.72%
Market Cap	4.97M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.29M	Perf Month	-44.80%
Enterprise Value	-5.67M	PEG	-	EPS next Q	-	Inst Own	5.16%	Short Float	5.13%	Perf Quarter	-41.53%
Income	-46.90M	P/S	11.83	EPS this Y	-	Inst Trans	-5.12%	Short Ratio	0.14	Perf Half Y	-88.04%
Sales	0.42M	P/B	0.14	EPS next Y	-	ROA	-95.40%	Short Interest	0.17M	Perf YTD	-72.72%
Book/sh	9.85	P/C	0.42	EPS next 5Y	-	ROE	-125.15%	52W High	46.50 -97.03%	Perf Year	-86.86%
Cash/sh	3.30	P/FCF	-	EPS past 3/5Y	-37.47% -	ROIC	-221.18%	52W Low	1.35 2.22%	Perf 3Y	-97.05%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-76.97% -64.54%	Gross Margin	-217.83%	Volatility	8.13% 13.56%	Perf 5Y	-99.48%
Dividend TTM	-	EV/Sales	-13.50	EPS Y/Y TTM	15.01%	Oper. Margin	-7529.23%	ATR (14)	0.27	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.59	Sales Y/Y TTM	-45.69%	Profit Margin	-11213.62%	RSI (14)	36.57	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.87	EPS Q/Q	-22.74%	SMA20	-23.17%	Beta	1.31	Target Price	45.00
Payout	-	Debt/Eq	0.06	Sales Q/Q	-60.06%	SMA50	-37.15%	Rel Volume	0.12	Prev Close	1.38
Employees	115	LT Debt/Eq	0.03	Earnings	Mar 31 AMC	SMA200	-81.49%	Avg Volume	1.19M	Price	1.38
IPO	Jul 12, 2017	Option/Short	No / Yes	EPS/Sales Surpr.	-354.17% 108.50%	Trades		Volume	54,337	Change	0.00%

Apr-14-26 09:00AM	Co-Diagnostics to Showcase Co-Dx PCR Platform and CE-IVD Solutions at ESCMID 2026 in Munich, Germany (PR Newswire)
Apr-09-26 09:00AM	Co-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC Utah (PR Newswire)
Apr-02-26 09:00AM	Co-Diagnostics Joint Venture CoMira Receives Approval for Manufacturing Facility in Kingdom of Saudi Arabia's Sudair Industrial City (PR Newswire)
Apr-01-26 08:30AM	Co-Diagnostics, Inc. Q4 2025 Earnings Call Summary (Moby) -12.90%
Mar-31-26 11:02PM	Co-Diagnostics Inc (CODX) Q4 2025 Earnings Call Highlights: Strategic Expansions and Financial ... (GuruFocus.com) +9.41%
04:01PM	Loading…
04:01PM	Co-Diagnostics Reports Full Year 2025 Financial Results (PR Newswire)
Mar-25-26 08:00AM	Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health Organization (PR Newswire) -13.22%
Mar-20-26 03:30PM	Co-Diagnostics (CODX) Expands CoSara Distribution Territory Across South Asia (NewMediaWire)

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CODX

Co-Diagnostics Inc

Upgrade your Finviz experience